MDNAF — Medicenna Therapeutics Corp.

OTC · Health Care · Pharmaceuticals · CIK 1807983 ·
Last close
$0.31
Market Cap
$26.14M
52W High
$0.69
52W Low
$0.30
ADV30
89,533
Next earnings
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 0 -5,616,000 -4,364,000 13,065,000 10,614,000 6,853,000
Sep 2025 0 -5,470,000 -4,883,000 18,041,000 15,748,000 7,799,000
Jun 2025 0 -5,509,000 -4,928,000 22,770,000 20,459,000 8,129,000
Mar 2025 0 -5,719,000 1,187,000 28,382,000 24,837,000 9,287,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,444,000
Investing CF
$2,000
Financing CF
$-18,000
CapEx
$-2,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.24
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-132,427,000
Inventory
Receivables
$1,465,000
ST Investments
EBIT TTM
$-22,314,000
Pretax Income TTM
$-12,988,000
Interest Exp TTM
Analysts
2

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2025 0 -20,406,000 -11,805,000 28,382,000 9,287,000 -16,492,000
Mar 2024 0 -18,674,000 -25,466,000 19,134,000 13,943,000 -16,260,000
Mar 2023 0 -16,303,000 -10,048,000 36,446,000 6,960,000 -12,657,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.17

Peers — same industry

TickerNameMarket CapLastDaily %
TPST Tempest Therapeutics, Inc. $26.21M $1.77
CELU Celularity Inc $25.96M $0.90
PTN PALATIN TECHNOLOGIES INC $25.70M $14.44
OTLC Oncotelic Therapeutics, Inc. $26.67M $0.06
ALLR Allarity Therapeutics, Inc. $26.81M $1.68

News headlines (Yahoo Finance, 1h cache)

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
2026-05-22 11:00 · Yahoo
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
2026-05-19 11:00 · Yahoo
Medicenna Announces the Launch of a Marketed Public Offering of Securities
2026-05-13 20:01 · Yahoo
Medicenna Says First Patient Dosed in NEO-CYT Study
2026-05-12 12:10 · Yahoo
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
2026-05-12 11:00 · Yahoo
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
2026-04-30 11:30 · Yahoo
TSX Penny Stocks To Watch In April 2026
2026-04-27 19:05 · Yahoo
Medicenna Therapeutics Presents "Positive" MDNA113 Data at AACR Meeting
2026-04-21 11:45 · Yahoo
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
2026-04-21 11:30 · Yahoo
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
2026-04-14 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.